Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer

2018 ◽  
Vol 46 (5) ◽  
pp. 378-383 ◽  
Author(s):  
Abhishek Biswas ◽  
Marino E. Leon ◽  
Peter Drew ◽  
Sebastian Fernandez-Bussy ◽  
Larissa V. Furtado ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Performance ◽  
Nonsmall Cell Lung Cancer ◽  
Needle Aspiration ◽  
Endobronchial Ultrasound ◽  
Ultrasound Guided ◽  
Transbronchial Needle Aspiration ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kazuhito Miyazaki ◽  
Yuya Hirasawa ◽  
Masaharu Aga ◽  
Naoto Aiko ◽  
Yusuke Hamakawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Needle Aspiration ◽  
Small Cell ◽  
Endobronchial Ultrasound ◽  
Small Cell Lung ◽  
Ultrasound Guided ◽  
Transbronchial Needle Aspiration ◽  
Pathologic Diagnosis

AbstractEndobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is useful for diagnosing hilar and mediastinal lymph node enlargement; however, specimens obtained are often small and inadequate for pathologic diagnosis. In June 2017, EchoTip ProCore, a puncture needle with a side trap, was launched in Japan. In this single-center prospective interventional study, 57 patients with lymph nodes, intrapulmonary tumor or pleural mass were diagnosed using EBUS-TBNA with EchoTip ProCore between June 2017 and February 2020. EBUS-TBNA was performed for 57 patients and 53 patients had sufficient specimen for histologic diagnosis. The following pathologic subtypes were diagnosed: non-small cell lung cancer, 22; small cell lung cancer, 8; cancer of unknown primary, 2; neuroendocrine tumor (G2) recurrence, 1; lymphoma, 2; metastatic renal cell carcinoma, 3; thymoma recurrence, 1; sarcoidosis, 4; tuberculosis, 1; and non-malignancy, 9. In addition, the cytology showed Class V in 31 out of 57 cases (54.4%). In total, a definitive pathological diagnosis was obtained in 50 out of 57 cases (87.7%). The only complication was pneumonia caused by BAL simultaneously combined with EBUS-TBNA in one patient. Among 13 patients with inadequate specimens or without malignancy, only one patient was subsequently diagnosed with malignancy, and the median follow-up period was 300 days. EBUS-TBNA using EchoTip ProCore can obtain a sufficient specimen size for pathologic diagnosis.

Sign in / Sign up

Export Citation Format

Share Document